Institutional shares held 54.3 Million
341K calls
235K puts
Total value of holdings $6.98B
$43.9M calls
$30.2M puts
Market Cap $7.13B
55,491,200 Shares Out.
Institutional ownership 97.92%
# of Institutions 486


Latest Institutional Activity in RGEN

Top Purchases

Q3 2024
Price T Rowe Associates Inc Shares Held: 6.39M ($821M)
Q3 2024
Champlain Investment Partners, LLC Shares Held: 1.42M ($183M)
Q3 2024
Citadel Advisors LLC Shares Held: 516K ($66.3M)
Q3 2024
Harding Loevner LP Shares Held: 916K ($118M)
Q3 2024
Two Sigma Investments, LP Shares Held: 436K ($56M)

Top Sells

Q3 2024
Millennium Management LLC Shares Held: 119K ($15.3M)
Q3 2024
T. Rowe Price Investment Management, Inc. Shares Held: 27.7K ($3.56M)
Q3 2024
Invesco Ltd. Shares Held: 1.06M ($136M)
Q3 2024
Brown Capital Management LLC Shares Held: 1.12M ($144M)
Q3 2024
Voya Investment Management LLC Shares Held: 481K ($61.8M)

About RGEN

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.


Insider Transactions at RGEN

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
113K Shares
From 22 Insiders
Grant, award, or other acquisition 64.5K shares
Exercise of conversion of derivative security 44K shares
Open market or private purchase 4.82K shares
Sell / Disposition
115K Shares
From 10 Insiders
Sale (or disposition) back to the issuer 13.1K shares
Payment of exercise price or tax liability 20.5K shares
Bona fide gift 2K shares
Open market or private sale 79.5K shares

Track Institutional and Insider Activities on RGEN

Follow REPLIGEN CORP and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RGEN shares.

Notify only if

Insider Trading

Get notified when an Repligen Corp insider buys or sells RGEN shares.

Notify only if

News

Receive news related to REPLIGEN CORP

Track Activities on RGEN